20227-26-3Relevant academic research and scientific papers
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT
-
, (2022/02/11)
The present invention relates to a pharmaceutical composition for preventing, treating or alleviating cancer, containing a PLK1 inhibitor as an active ingredient, and a compound according to the present invention selectively binds to PBD of PLK1, thereby having advantages of high selectivity and binding affinity for PLK1 and low toxicity. Therefore, a PLK inhibitor compound according to the present invention can be effectively used as an anticancer agent by inhibiting the growth of various cancer cells, and can be expected to exhibit synergistic effects with existing developed anticancer agents through co-administration, in addition to individual administration thereof.
Synthesis and characterization of flavin-tethered peptide nucleic acid
Ikeda, Hisafumi,Yoshida, Kohzo,Ozeki, Makoto,Saito, Isao
, p. 2529 - 2531 (2007/10/03)
We synthesized flavin-containing PNA monomer unit 5 from lumiflavin and prepared PNAs containing a flavin moiety (FPNA) by the standard tBoc chemistry. Each PNA oligomer was purified by reversed-phase HPLC and characterized by MALDI-TOF MS and UV spectra. Thermodynamic analyses indicated that the PNA oligomer containing a flavin moiety near the amino terminal considerably stabilized the PNA-DNA hybrids.
